JAMA Network
About The Study: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.
Corresponding Author: To contact the corresponding author, Scott D. Solomon, MD, email [email protected].
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4539)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
